Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YES1 | P07947 | 2/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.46 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701368 | 0.88 | YES1 (0.50) | YES1FGFR2METCYP3A4IKBKB | |
| SCHEMBL3704091 | 0.86 | YES1 (0.48) | YES1FGFR2METCYP3A4IKBKB | |
| SCHEMBL3707719 | 0.85 | YES1 (0.47) | YES1FGFR2METCYP3A4IKBKB | |
| SCHEMBL3698189 | 0.84 | YES1 (0.46) | YES1FGFR2METCYP3A4IKBKB | |
| SCHEMBL2204168 | 0.81 | MAPT (0.53) | YES1FGFR2KDR | |
| SCHEMBL15663604 | 0.79 | MAPT (0.50) | FGFR2KDR | |
| SCHEMBL15663448 | 0.78 | FGFR2 (0.45) | YES1FGFR2METCYP3A4KDR | |
| SCHEMBL3694325 | 0.78 | FGFR2 (0.40) | YES1FGFR2METCYP3A4IKBKB | |
| SCHEMBL2209759 | 0.78 | FGFR2 (0.44) | YES1FGFR2KDRRIPK2EGFR | |
| SCHEMBL2209090 | 0.78 | FGFR2 (0.46) | YES1FGFR2KDRRIPK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | YES1 295/4885FGFR2 334/4885MET 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.